Business Context and Reporting Period
Company: Enanta Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 5, 2021
Reporting Period: The filing addresses a specific event occurring on the report date regarding the re-filing of a material agreement.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a procedural filing to disclose a previously confidential contract.
Material Changes
Re-filing of AbbVie Agreement: The Company is re-filing the "AbbVie Agreement" (comprising the Original Agreement with Abbott Laboratories dated November 27, 2006, and subsequent amendments through October 20, 2014) to comply with Item 601(b)(10)(iv) of Regulation S-K.
Confidential Treatment Expiration: The Securities and Exchange Commission previously granted confidential treatment for certain provisions of this agreement, which expired on February 5, 2021.
Guidance, Outlook, and Risks
Management Commentary: The filing states that certain portions of the attached exhibits have been redacted. The Company determined that the omitted information is not material and would likely cause competitive harm if publicly disclosed.
Risks and Contingencies: No new risks or contingencies are disclosed in this specific report beyond the standard redaction of competitive information within the contract exhibits.
Key Facts for Investor Verification
- The filing is a compliance update to make the full text of the AbbVie collaboration agreement public following the expiration of confidential treatment.
- The agreement involves a collaborative development and license relationship with AbbVie Inc. (formerly Abbott Laboratories).
- Specific financial terms and certain provisions within the agreement remain redacted in the public filing.
- No operational or financial performance updates are included in this document.